Bio-Techne vs Danaher: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Bio-Techne Corp (TECH)

Q3 202628 Jun – 23 Sep 2026

▲3

Bio-Techne's $73-a-share Merck buyout clears shareholder vote and antitrust review

Shareholders approve Merck KGaA buyout On September 23, 2026, Bio-Techne shareholders voted to approve the $73-per-share cash buyout by Merck KGaA. This locks in the deal price and moves the company closer to closing, so the stock should trade near $73 rather than on its own business results.
This is the latest and most important step in the buyout that now defines TECH's price.
Antitrust waiting period expires The U.S. antitrust waiting period under the Hart-Scott-Rodino Act expired on September 18, 2026. That removes a major regulatory hurdle, making it more likely the deal closes on schedule and reducing the risk that the $73 price falls through.
It is a new, concrete regulatory clearance that directly supports deal completion.
Merck KGaA confirms deal on track Merck KGaA raised its 2026 outlook on August 6 and said it still expects to close the Bio-Techne purchase by late 2026 or early 2027, with about 140 million euros in annual cost savings. A healthy buyer with a firm timeline makes the $73 payout more certain.
It shows the acquirer is financially strong and committed, which supports the deal price.
Weak quarterly sales and legal probe Bio-Techne's revenue fell 1.5% to $311.4 million, missing estimates, and a law firm is investigating whether the board handled the buyout fairly. These are minor now because the $73 cash deal caps the stock, but they could matter if the deal breaks.
It gives the fair counterweight: the company's own results are soft and the deal faces a legal review.

August 202628 Jun – 23 Sep 2026

▲3

Bio-Techne's $73-a-share Merck buyout clears shareholder vote and antitrust review

Shareholders approve Merck KGaA buyout On September 23, 2026, Bio-Techne shareholders voted to approve the $73-per-share cash buyout by Merck KGaA. This locks in the deal price and moves the company closer to closing, so the stock should trade near $73 rather than on its own business results.
This is the latest and most important step in the buyout that now defines TECH's price.
Antitrust waiting period expires The U.S. antitrust waiting period under the Hart-Scott-Rodino Act expired on September 18, 2026. That removes a major regulatory hurdle, making it more likely the deal closes on schedule and reducing the risk that the $73 price falls through.
It is a new, concrete regulatory clearance that directly supports deal completion.
Merck KGaA confirms deal on track Merck KGaA raised its 2026 outlook on August 6 and said it still expects to close the Bio-Techne purchase by late 2026 or early 2027, with about 140 million euros in annual cost savings. A healthy buyer with a firm timeline makes the $73 payout more certain.
It shows the acquirer is financially strong and committed, which supports the deal price.
Weak quarterly sales and legal probe Bio-Techne's revenue fell 1.5% to $311.4 million, missing estimates, and a law firm is investigating whether the board handled the buyout fairly. These are minor now because the $73 cash deal caps the stock, but they could matter if the deal breaks.
It gives the fair counterweight: the company's own results are soft and the deal faces a legal review.

Latest28 Jun – 23 Sep 2026

▲3

Bio-Techne's $73-a-share Merck buyout clears shareholder vote and antitrust review

Shareholders approve Merck KGaA buyout On September 23, 2026, Bio-Techne shareholders voted to approve the $73-per-share cash buyout by Merck KGaA. This locks in the deal price and moves the company closer to closing, so the stock should trade near $73 rather than on its own business results.
This is the latest and most important step in the buyout that now defines TECH's price.
Antitrust waiting period expires The U.S. antitrust waiting period under the Hart-Scott-Rodino Act expired on September 18, 2026. That removes a major regulatory hurdle, making it more likely the deal closes on schedule and reducing the risk that the $73 price falls through.
It is a new, concrete regulatory clearance that directly supports deal completion.
Merck KGaA confirms deal on track Merck KGaA raised its 2026 outlook on August 6 and said it still expects to close the Bio-Techne purchase by late 2026 or early 2027, with about 140 million euros in annual cost savings. A healthy buyer with a firm timeline makes the $73 payout more certain.
It shows the acquirer is financially strong and committed, which supports the deal price.
Weak quarterly sales and legal probe Bio-Techne's revenue fell 1.5% to $311.4 million, missing estimates, and a law firm is investigating whether the board handled the buyout fairly. These are minor now because the $73 cash deal caps the stock, but they could matter if the deal breaks.
It gives the fair counterweight: the company's own results are soft and the deal faces a legal review.

Q2 202625 Jun – 26 Jun 2026

▲1▼1

Merck KGaA to buy Bio-Techne for $73/share in $11.3B cash deal

Merck KGaA acquisition at $73/share cash Germany's Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, a 36% premium to its recent average price. This puts a firm floor under the stock near the deal price and is the main reason shares jumped about 20%.
This is the single new event that explains the stock's move and future path.
Deal completion risk and timeline The deal needs regulatory approvals and a shareholder vote, and is expected to close in late 2026 or early 2027. Until then, the stock may trade below $73 if investors worry the deal could fall through, but the agreed price limits big downside.
It is the main counterweight: the deal is not yet final, so the premium is not guaranteed.
Weak underlying quarterly revenue Bio-Techne's latest quarterly revenue fell 1.5% to $311.4 million and missed expectations. This weak operating performance is now less important because the company is being bought, but it shows why the standalone business was struggling.
It explains the weak standalone backdrop that the buyout overrides, giving a fair picture.

June 202625 Jun – 26 Jun 2026

▲1▼1

Merck KGaA to buy Bio-Techne for $73/share in $11.3B cash deal

Merck KGaA acquisition at $73/share cash Germany's Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, a 36% premium to its recent average price. This puts a firm floor under the stock near the deal price and is the main reason shares jumped about 20%.
This is the single new event that explains the stock's move and future path.
Deal completion risk and timeline The deal needs regulatory approvals and a shareholder vote, and is expected to close in late 2026 or early 2027. Until then, the stock may trade below $73 if investors worry the deal could fall through, but the agreed price limits big downside.
It is the main counterweight: the deal is not yet final, so the premium is not guaranteed.
Weak underlying quarterly revenue Bio-Techne's latest quarterly revenue fell 1.5% to $311.4 million and missed expectations. This weak operating performance is now less important because the company is being bought, but it shows why the standalone business was struggling.
It explains the weak standalone backdrop that the buyout overrides, giving a fair picture.

25 Jun – 26 Jun 2026

▲1▼1

Merck KGaA to buy Bio-Techne for $73/share in $11.3B cash deal

Merck KGaA acquisition at $73/share cash Germany's Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, a 36% premium to its recent average price. This puts a firm floor under the stock near the deal price and is the main reason shares jumped about 20%.
This is the single new event that explains the stock's move and future path.
Deal completion risk and timeline The deal needs regulatory approvals and a shareholder vote, and is expected to close in late 2026 or early 2027. Until then, the stock may trade below $73 if investors worry the deal could fall through, but the agreed price limits big downside.
It is the main counterweight: the deal is not yet final, so the premium is not guaranteed.
Weak underlying quarterly revenue Bio-Techne's latest quarterly revenue fell 1.5% to $311.4 million and missed expectations. This weak operating performance is now less important because the company is being bought, but it shows why the standalone business was struggling.
It explains the weak standalone backdrop that the buyout overrides, giving a fair picture.

Danaher Corporation (DHR)

Q3 202624 Jun – 4 Aug 2026

▼3▲1

Danaher's Masimo Deal and Guidance Cut Pressure Shares

Masimo Acquisition Drag Danaher's $9.9 billion purchase of Masimo sent shares down 22% due to debt, integration challenges, and Apple patent disputes. This major deal overshadowed positive product news.
The acquisition is the biggest new event and main reason for the stock's decline.
Guidance Cut on Weak Respiratory Testing Danaher lowered its full-year core revenue growth forecast to 4% from 6%, blaming weaker respiratory testing and over $100 million in bioprocessing revenue shifting to 2027.
This guidance cut directly impacts investor expectations and the stock's valuation.
Biotech Consumables Shipment Timing Miss Biotech consumables missed expectations due to shipment timing, raising fears of broader weakness despite strong underlying demand. This added to concerns about the bioprocessing business.
The miss highlights execution risks and weighs on sentiment.
Strong Biotech Growth and Product Approvals Danaher posted 7% core biotech growth, strong bioprocessing orders, FDA clearance for Masimo's AI opioid-detection feature, and a CE Mark for Beckman Coulter's Alzheimer's blood test. Q2 EPS beat and guidance was raised.
These positives show underlying business strength and innovation, providing a counterweight to the negatives.

July 202624 Jun – 4 Aug 2026

▼3▲1

Danaher's Masimo Deal and Guidance Cut Pressure Shares

Masimo Acquisition Drag Danaher's $9.9 billion purchase of Masimo sent shares down 22% due to debt, integration challenges, and Apple patent disputes. This major deal overshadowed positive product news.
The acquisition is the biggest new event and main reason for the stock's decline.
Guidance Cut on Weak Respiratory Testing Danaher lowered its full-year core revenue growth forecast to 4% from 6%, blaming weaker respiratory testing and over $100 million in bioprocessing revenue shifting to 2027.
This guidance cut directly impacts investor expectations and the stock's valuation.
Biotech Consumables Shipment Timing Miss Biotech consumables missed expectations due to shipment timing, raising fears of broader weakness despite strong underlying demand. This added to concerns about the bioprocessing business.
The miss highlights execution risks and weighs on sentiment.
Strong Biotech Growth and Product Approvals Danaher posted 7% core biotech growth, strong bioprocessing orders, FDA clearance for Masimo's AI opioid-detection feature, and a CE Mark for Beckman Coulter's Alzheimer's blood test. Q2 EPS beat and guidance was raised.
These positives show underlying business strength and innovation, providing a counterweight to the negatives.

Latest25 Jul – 4 Aug 2026

▲3▼1

Danaher cuts growth outlook, but core biotech and diagnostics still support

Full-year core revenue growth outlook cut to 4% from 6% Danaher lowered the top end of its 2026 core revenue growth forecast to 4% from 6%, citing weaker respiratory testing and over $100 million in bioprocessing revenue shifting to next year. This signals slower demand ahead, pushing the stock down as investors worry about future growth.
This is the main new negative event that directly answers why DHR is moving right now.
Q2 earnings beat and raised EPS guidance Danaher reported adjusted EPS of $1.94, beating estimates, and raised full-year EPS guidance to $8.45–$8.60. This shows the core business remains profitable and resilient, which could support the stock once the sell-off settles.
This is a new positive counterweight that helps explain the mixed picture and potential support for the stock.
Biotech orders grow mid-teens, but revenue timing shifts Danaher's bioprocessing orders grew mid-teens, indicating strong underlying demand, but weaker-than-expected biotechnology revenue and a shift of over $100 million into next year weighed on results. This creates a mixed picture: strong future demand but near-term revenue miss.
This explains the nuance behind the revenue miss and why the stock reaction may be overdone.
Analysts see stock as undervalued after sell-off A Simply Wall St analysis suggests Danaher is 16% undervalued based on earnings and 2026 revenue guidance, with a fair value estimate of $228.61. BofA maintained a Buy rating but cut its price target to $230 from $270. This could attract value investors and support the stock.
This provides a potential positive catalyst and shows analyst views on valuation after the decline.

17 Jul – 24 Jul 2026

▲2▼2

Danaher's Q2 Beat Marred by Weak Guidance and Biotech Shipment Shift

Weak Q3 revenue guidance triggers sell-off Danaher guided Q3 core revenue growth to just 2-3%, far below expectations, despite beating Q2 estimates. This signals slower demand ahead, pushing the stock down sharply as investors worry about future growth.
This is the main new event that caused the stock to drop over 10% this period.
Biotech consumables sales miss due to shipment timing High-margin biotech consumables missed expectations because a few large chromatography resin shipments moved out of the year. This reduces near-term revenue and profit, and the market fears it could signal broader weakness.
This explains the specific reason behind the guidance cut and the stock's decline.
Q2 earnings beat and raised full-year EPS guidance Danaher reported adjusted EPS of $1.94, beating estimates, and raised full-year EPS guidance to $8.45-$8.60. This shows the core business remains profitable and resilient, which could support the stock once the sell-off settles.
This is a key positive from the quarter that contrasts with the negative reaction.
Analysts see sell-off as overreaction and buying opportunity The 12% weekly drop is viewed by some analysts as an overreaction to a timing issue, not a fundamental problem. If shipments shift to later quarters, revenue will still be recognized, making the decline a potential buying opportunity for long-term investors.
This provides a counterweight to the negative news and suggests the stock may rebound.

24 Jun – 9 Jul 2026

▲3▼1

Danaher's Masimo Bet Faces Doubts as Core Biotech Shows Strength

Masimo acquisition drags on stock Danaher's $9.9 billion purchase of Masimo has pushed shares down 22% this year. Investors worry about added debt, integration challenges, and a patent fight with Apple. This weighs on the stock because it increases risk and uncertainty.
Explains the main reason DHR is down this year and the key overhang on the stock.
Masimo unit gets FDA clearance for AI opioid detection Masimo received FDA clearance for an AI feature that detects opioid-induced breathing problems. This is a first-of-its-kind product that could boost sales and shows the acquisition is already producing innovative products, lifting investor sentiment.
Shows a concrete positive from the Masimo deal that could drive future revenue and improve sentiment.
Biotech segment core revenues grow 7% Danaher's Biotechnology segment saw core revenues rise 7% in Q1 2026, with bioprocessing equipment orders up over 30%. This indicates strong demand for the company's core products, which supports revenue growth and profitability, pushing the stock up.
Highlights the strong performance of Danaher's core business, a key driver of earnings and stock price.
Beckman Coulter wins CE Mark for Alzheimer's blood test Danaher's Beckman Coulter received CE Mark for its p-Tau217 blood assay, allowing sales in Europe. This regulatory win opens a new market for a potentially high-demand Alzheimer's test, adding a future revenue stream and boosting the stock.
Represents a new product approval that expands Danaher's diagnostics offerings and could drive growth.